Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022
PDF Version

 

In an interview, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma (MZL) and Waldenström’s macroglobulinemia (WM).

Dr Gandhi further explains the connection of Bruton tyrosine kinase inhibitors with MZL and WM while examining data from various trials.


 

Advertisement

Advertisement

Advertisement